Drug intelligence / Profile preview

poterepatide

Development stage: Phase 3
Lead developer: Hangzhou Zhongmei Huadong Pharmaceutical
Modality: Peptides
Administration: Subcutaneous

Overview

Poterepatide (HDM1005) is a novel, long-acting synthetic peptide developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. It functions as a dual agonist for the Glucagon-like peptide-1 receptor (GLP-1R) and the Gastric inhibitory polypeptide receptor (GIPR). This dual agonism promotes insulin release, suppresses appetite, and improves glucose tolerance, leading to significant weight loss primarily through fat mass reduction. Poterepatide is currently in clinical development for the treatment of Type 2 Diabetes Mellitus and obesity.

Other names: HDM-1005HDM1005HDM 1005

Targets

GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)

Beyond the preview

Go deeper on poterepatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on poterepatide.

Explore the full profile